|
|
|
| Construction of a nanoformulation with active targeting and preliminary study on its in vitro pharmacodynamics |
| LIU Miao1 PENG Ying2 ZHOU Xingchen3 |
1.Department of Pharmacy, Hunan Cancer Hospital, Hunan Province, Changsha 410011, China;
2.Xiangya School of Pharmaceutical Sciences, Central South University, Hunan Province, Changsha 410013, China;
3.Department of Pharmacy, Xiangya Hospital, Central South University, Hunan Province, Changsha 410008, China |
|
|
|
Abstract Objective To construct an active targeting nanoformulation loaded with the chemotherapeutic Doxorubicin (DOX). Methods PLGA/DOX@PDA-PEG-FA nanoformulations were prepared by using polylactic acid-glycolic acid copolymer (PLGA), DOX, dopamine (DA), amino-modified polyethylene glycol folic acid (NH2-PEG-FA). Particle size, potential, drug loading, encapsulation efficiency, drug release characteristics were characterized, and cell uptake, biocompatibility, cytotoxicity were preliminarily discussed by fluorescence inverted microscope and thiazolyl blue (MTT) colorimetry. Results In this study, PLGA/DOX@PDA-PEG-FA nano-formulations were successfully prepared, which had an obvious core-shell structure with a particle size of about 120 nm, a shell thickness of about 18 nm, and ζ potential of -18.1 mV. The encapsulation efficiency and drug loading were 43.56% and 1.86%, respectively, and it had obvious sustained-release properties. MTT assay showed that the carrier material had good biocompatibility and the cytotoxicity was dose-dependent. Conclusion The nanocomposite prepared in this experiment has good biocompatibility and anti-tumor effect in vitro. The preparation provides a new idea for the wide application of PLGA and the effective reduction of adverse reactions of chemotherapy drugs.
|
|
|
|
|
|
[1] Sung H，Ferlay J，Siegel RL，et al. Global Cancer Statistics 2020：GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries [J]. CA Cancer J Clin，2021，71（3）：209-249.
[2] Fan WP，Yung B，Huang P，et al. Nanotechnology for Multimodal Synergistic Cancer Therapy [J]. Chem Rev，2017，117（22）：13566-13638.
[3] Xie Z，Fan T，An J，et al. Emerging combination strategies with phototherapy in cancer nanomedicine [J]. Chem Soc Rev，2020，49（22）：8065-8087.
[4] Beck WT，Danks MK. Mechanisms of resistance to drugs that inhibit DNA topoisomerases [J]. Semin Cancer Biol，1991，2（4）：235-244.
[5] Benjanuwattra J，Siri-Angkul N，Chattipakorn SC，et al. Doxorubicin and its proarrhythmic effects：A comprehensive review of the evidence from experimental and clinical studies [J]. Pharmacol Res，2020，151：104502.
[6] Vasan N，Baselga J，Hyman DM. A view on drug resistance in cancer [J]. Nature，2019，575（7782）：299-309.
[7] Xu J，Shamul JG，Wang H，et al. Targeted Heating of Mitochondria Greatly Augments Nanoparticle-Mediated Cancer Chemotherapy [J]. Adv Healthc Mater，2020，9（14）：e2000181.
[8] Martinez-Garcia D，Manero-Ruperez N，Quesada R，et al.，Therapeutic strategies involving survivin inhibition in cancer [J]. Med Res Rev，2019，39（3）：887-909.
[9] Yang K，Liu Y，Liu Y，et al. Cooperative Assembly of Magneto-Nanovesicles with Tunable Wall Thickness and Permeability for MRI-Guided Drug Delivery [J]. J Am Chem Soc，2018，140（13）：4666-4677.
[10] Pei P，Sun CY，Tao W，et al. ROS-sensitive thioketal- linked polyphosphoester-doxorubicin conjugate for precise phototriggered locoregional chemotherapy [J]. Biomaterials，2019，188：74-82.
[11] Shi J，Kantoff PW，Wooster R，et al. Cancer nanomedicine：progress，challenges and opportunities [J]. Nat Rev Cancer，2017，17（1）：20-37.
[12] Su Y，Zhang BL，Sun RW，et al. PLGA-based biodegradable microspheres in drug delivery：recent advances in research and application [J]. Drug Deliv，2021，28（1）：1397-1418.
[13] Rocha CV，Goncalves V，Silva MC，et al. PLGA-Based Composites for Various Biomedical Applications [J]. Int J Mol Sci，2022，23（4）：2034.
[14] El Yakhlifi S，Ball V. Polydopamine as a stable and functional nanomaterial [J]. Colloids Surf B Biointerfaces，2020， 186：110719.
[15] Zheng P，Ding BB，Li G. Polydopamine-Incorporated Nano- formulations for Biomedical Applications [J]. Macromol Biosci，2020，20（12）：e2000228.
[16] Liu M，Peng Y，Nie YB，et al. Co-delivery of doxorubicin and DNAzyme using ZnO@polydopamine core-shell nanocomposites for chemo/gene/photothermal therapy [J]. Acta Biomater，2020，110：242-253.
[17] Wang Z，Duan YO，Duan YW. Application of polydopamine in tumor targeted drug delivery system and its drug release behavior [J]. J Control Release，2018，290：56-74.
[18] Sen Gupta A. Role of particle size，shape，and stiffness in design of intravascular drug delivery systems：insights from computations，experiments，and nature [J]. Wiley Interdiscip Rev Nanomed Nanobiotechnol，2016，8（2）：255-270.
[19] Miller T，Rachel R，Besheer A，et al. Comparative Investigations on In Vitro Serum Stability of Polymeric Micelle Formulations [J]. Pharm Res，2012，29（2）：448-459.
[20] Zhang J，Cui YX，Feng XN，et al. pH-Controlled Intracellular in Situ Reversible Assembly of a Photothermal Agent for Smart Chemo-Photothermal Synergetic Therapy and ATP Imaging [J]. Acs App Mater Interfaces，2019，11（43）：39624-39632.
[21] Wang YG，Zhou KJ，Huang G，et al. A nanoparticle-based strategy for the imaging of a broad range of tumours by nonlinear amplification of microenvironment signals [J]. Nat Mater，2014，13（2）：204-212.
[22] Noh J，Kwon B，Han E，et al. Amplification of oxidative stress by a dual stimuli-responsive hybrid drug enhances cancer cell death [J]. Nat Commun，2015，6：6907.
[23] Wang X，Zhang J，Wang Y，et al. Multi-responsive photothermal-chemotherapy with drug-loaded melanin-like nanoparticles for synergetic tumor ablation [J]. Biomaterials，2016，81：114-124.
[24] Narmani A，Rezvani M，Farhood B，et al. Folic acid functionalized nanoparticles as pharmaceutical carriers in drug delivery systems [J]. Drug Dev Res，2019，80（4）：404-424.
[25] Zhang W，Torabinejad M，Li YM. Evaluation of cytotoxicity of MTAD using the MTT-tetrazolium method [J]. J Endod，2003，29（10）：654-657. |
|
|
|
